Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Toxoplasma gondii | flavodoxin domain-containing protein | 0.058 | 0.1841 | 0.5 |
Echinococcus multilocularis | NADPH dependent diflavin oxidoreductase 1 | 0.1169 | 1 | 1 |
Schistosoma mansoni | cytochrome P450 reductase | 0.1169 | 1 | 1 |
Loa Loa (eye worm) | FAD binding domain-containing protein | 0.0722 | 0.3805 | 0.3805 |
Mycobacterium ulcerans | formate dehydrogenase H FdhF | 0.1169 | 1 | 0.5 |
Trypanosoma brucei | NADPH-cytochrome p450 reductase, putative | 0.1169 | 1 | 1 |
Giardia lamblia | Nitric oxide synthase, inducible | 0.1036 | 0.8159 | 0.5 |
Brugia malayi | FAD binding domain containing protein | 0.1169 | 1 | 1 |
Schistosoma mansoni | NADPH flavin oxidoreductase | 0.0589 | 0.1964 | 0.0151 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.1169 | 1 | 1 |
Plasmodium vivax | NADPH-cytochrome p450 reductase, putative | 0.1169 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.1169 | 1 | 1 |
Entamoeba histolytica | type A flavoprotein, putative | 0.0447 | 0 | 0.5 |
Echinococcus multilocularis | NADPH cytochrome P450 reductase | 0.1169 | 1 | 1 |
Loa Loa (eye worm) | FAD binding domain-containing protein | 0.1169 | 1 | 1 |
Trichomonas vaginalis | sulfite reductase, putative | 0.1169 | 1 | 1 |
Echinococcus granulosus | NADPH dependent diflavin oxidoreductase 1 | 0.1169 | 1 | 1 |
Entamoeba histolytica | type A flavoprotein, putative | 0.0447 | 0 | 0.5 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.1169 | 1 | 1 |
Echinococcus granulosus | NADPH cytochrome P450 reductase | 0.1169 | 1 | 1 |
Giardia lamblia | Hypothetical protein | 0.1036 | 0.8159 | 0.5 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.058 | 0.1841 | 0.5 |
Trichomonas vaginalis | NADPH fad oxidoreductase, putative | 0.1036 | 0.8159 | 0.8159 |
Leishmania major | p450 reductase, putative | 0.1169 | 1 | 1 |
Schistosoma mansoni | 5-methyl tetrahydrofolate-homocysteine methyltransferase reductase | 0.0722 | 0.3805 | 0.2407 |
Brugia malayi | FAD binding domain containing protein | 0.0722 | 0.3805 | 0.3805 |
Plasmodium vivax | flavodoxin domain containing protein | 0.1036 | 0.8159 | 0.8159 |
Entamoeba histolytica | type A flavoprotein, putative | 0.0447 | 0 | 0.5 |
Entamoeba histolytica | type A flavoprotein, putative | 0.0447 | 0 | 0.5 |
Treponema pallidum | flavodoxin | 0.0447 | 0 | 0.5 |
Trypanosoma brucei | NADPH-dependent diflavin oxidoreductase 1 | 0.1169 | 1 | 1 |
Plasmodium falciparum | nitric oxide synthase, putative | 0.1169 | 1 | 1 |
Leishmania major | NADPH-cytochrome p450 reductase-like protein | 0.1169 | 1 | 1 |
Leishmania major | cytochrome P450 reductase, putative | 0.1036 | 0.8159 | 0.8159 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.1169 | 1 | 1 |
Trypanosoma cruzi | NADPH-dependent FMN/FAD containing oxidoreductase, putative | 0.1169 | 1 | 1 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.1169 | 1 | 1 |
Entamoeba histolytica | type A flavoprotein, putative | 0.0447 | 0 | 0.5 |
Trypanosoma cruzi | p450 reductase, putative | 0.1169 | 1 | 1 |
Chlamydia trachomatis | sulfite reductase | 0.0722 | 0.3805 | 0.5 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.